0.24
0.24 (0%)
As of Apr 17, 2025
Adaptimmune Therapeutics Plc [ADAP]
Source:
Company Overview
Adaptimmune Therapeutics Plc is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. With the approval by the U.S. Food and Drug Administration (“FDA”) of our first biologics license application (“BLA”) for TECELRA (afamitresgene autoleucel) (“TECELRA”), which is the first engineered T-cell therapy for the treatment of a solid tumor cancer approved in the U.S., we are now focused on its launch and commercialization.
| Country | United Kingdom |
| Headquarters | abingdon,, oxfordshire |
| Phone Number | (44) 1235 430000 |
| Industry | manufacturing |
| CEO | Adrian Rawcliffe |
| Website | www.adaptimmune.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $178 |
| Operating Profit | $-68.8 |
| Net Income | $-70.8 |
| Net Cash | $-53.8 |
Profit Ratios
| Gross Margin | $178.1 |
| Operating Margin | -38.6 |
| Profit as % of Revenues | -251.5% |
| Profit as % of Assets | -26.8% |
| Profit as % of Stockholder Equity | -597.6% |
Management Effectiveness
| Return on Equity | -597.6% |
| Return on Assets | -28.8% |
| Turnover Ratio | 67.4% |
| EBITA | $-68.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $246 |
| Total Liabilities | $234.1 |
| Operating Cash Flow | $-73.2 |
| Investing Cash Flow | $-59 |
| Financing Cash Flow | $78.7 |
